TABLE 2.
Summary of clinical and pathological characteristics associated with cases in the TB Portalsa
| Parameter | No. (%) of cases |
Total no. of cases | |||||
|---|---|---|---|---|---|---|---|
| XDR | Monoresistance | MDR | NR | In progress | PDR | ||
| Resistance test results determined by: | |||||||
| GeneXpert | 45 (15.3) | 9 (20.9) | 150 (22.0) | 36 (20.9) | 2 (2.4) | 5 (20.8) | 247 |
| Hain test | 57 (19.4) | 4 (9.3) | 103 (15.1) | 11 (6.4) | 1 (1.2) | 0 (0.0) | 176 |
| Unspecified test | 95 (32.3) | 18 (41.9) | 234 (34.3) | 52 (30.2) | 2 (2.4) | 11 (45.8) | 412 |
| Lowenstein-Jensen test | 165 (56.1) | 10 (23.3) | 270 (39.6) | 43 (25.0) | 10 (11.9) | 5 (20.8) | 503 |
| No. of X-ray images | |||||||
| At least 1 | 113 (38.4) | 18 (41.9) | 234 (34.3) | 77 (44.8) | 40 (47.6) | 14 (58.3) | 496 |
| At least 2 | 56 (19.0) | 10 (23.3) | 121 (17.7) | 55 (32.0) | 0 (0.0) | 6 (25.0) | 248 |
| At least 3 | 39 (13.3) | 8 (18.6) | 64 (9.4) | 36 (20.9) | 0 (0.0) | 3 (12.5) | 150 |
| No. of CT scans | |||||||
| At least 1 | 170 (57.8) | 26 (60.5) | 341 (50.0) | 116 (67.4) | 9 (10.7) | 13 (54.2) | 675 |
| At least 2 | 68 (23.1) | 11 (25.6) | 156 (22.9) | 40 (23.3) | 9 (10.7) | 1 (4.2) | 285 |
| At least 3 | 40 (13.6) | 7 (16.3) | 118 (17.3) | 28 (16.3) | 9 (10.7) | 1 (4.2) | 203 |
| Lung localization(s) | |||||||
| Extrapulmonary tuberculosis | 3 (1.0) | 1 (2.3) | 6 (0.9) | 0 (0.0) | 1 (1.2) | 0 (0.0) | 11 |
| Pulmonary tuberculosis | 238 (81.0) | 30 (69.8) | 547 (80.2) | 131 (76.2) | 78 (92.9) | 17 (70.8) | 1,041 |
| Pulmonary tuberculosis and extrapulmonary tuberculosis | 52 (17.7) | 12 (27.9) | 124 (18.2) | 40 (23.3) | 2 (2.4) | 7 (29.2) | 237 |
| Affecting pleura | |||||||
| No | 16 (5.4) | 8 (18.6) | 70 (10.3) | 45 (26.2) | 0 (0.0) | 7 (29.2) | 146 |
| Yes | 64 (21.8) | 10 (23.3) | 143 (21.0) | 50 (29.1) | 0 (0.0) | 5 (20.8) | 272 |
| Lung cavity size (mm) | |||||||
| <10–25 | 28 (9.5) | 1 (2.3) | 33 (4.8) | 9 (5.2) | 8 (9.5) | 0 (0.0) | 79 |
| <10 | 22 (7.5) | 6 (14.0) | 69 (10.1) | 20 (11.6) | 7 (8.3) | 5 (20.8) | 129 |
| >25 | 28 (9.5) | 2 (4.7) | 39 (5.7) | 4 (2.3) | 5 (6.0) | 2 (8.3) | 80 |
| No lung cavity | 28 (9.5) | 11 (25.6) | 130 (19.1) | 63 (36.6) | 9 (10.7) | 6 (25.0) | 247 |
| No. of regimens during treatment | |||||||
| 1 | 219 (74.5) | 26 (60.5) | 491 (72.0) | 132 (76.7) | 43 (51.2) | 17 (70.8) | 928 |
| 2 | 21 (7.1) | 5 (11.6) | 49 (7.2) | 3 (1.7) | 3 (3.6) | 3 (12.5) | 84 |
| 3+ | 33 (11.2) | 1 (2.3) | 86 (12.6) | 4 (2.3) | 1 (1.2) | 2 (8.3) | 127 |
a
Resistance definitions are as follows: monoresistance is resistance to one first-line anti-TB drug only, polydrug resistance is resistance to more than one first-line anti-TB drug (other than both isoniazid and rifampin), multidrug resistance is resistance to at least both isoniazid and rifampin, and extensive drug resistance is resistance to any fluoroquinolone and to at least one of 3 second-line injectable drugs (capreomycin, kanamycin, and amikacin) in addition to multidrug resistance. “In progress” describes cases whose full case data entry is not yet complete.